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Summary.-Previous studies, using plasmapheresis to remove blocking factors of
cell-mediated cytotoxity to melanoma cells from the circulation of melanoma
patients, suggested that leucocyte-dependent antibody to melanoma cells may also
be blocked by factors in their sera. The present study confirms these findings, by
showing that most patients with disseminated melanoma had melanoma LDA
activity in the IgG fraction when this was separated from their sera. This also applied
to a high percentage of patients with primary melanoma. Evidence that the blocking
factors may be immune complexes was shown by experiments in which LDA activity
to melanoma cells was revealed after acidification of melanoma sera to dissociate
immune complexes, followed by ultrafiltration through membranes retaining mole-
cules of size greater than 100,000 daltons. Blocking of LDA activity in the retentate
recurred when the retentate was recombined with the filtrate. Further studies
indicated that the blocking activity showed affinity for the target cell and not the
effector cell. Preliminary analysis of the specificity of the blocking suggests that this
was similar to that of melanoma antisera.
These results appear to show that blocking of LDA activity to melanoma cells is
common in melanoma patients and that the assay system may provide a quantitative
method for their analysis that may yield information of biological importance in the
management of melanoma patients.
THE presence of blocking factors which
inhibit cell-mediated cytotoxicity (CMC)
against tumour cells appears to provide
one of the more important mechanisms
for escape of tumours from the immune
cytotoxic response of the host. Serum
factors having this activity have been
demonstrated in both animal (Hellstr6m
and Hellstrim, 1969; Bansal and Sjogren,
1971, 1973; Baldwin, Price and Robins,
1972, 1973; Thompson, Eccles and Alex-
ander, 1973) and human studies (Hell-
strom et al., 1971; Currie and Basham,
1972; Baldwin, Embleton and Price,
1973; Jose and Seshadri, 1974). In
particular, studies on melanoma subjects
appear to confirm the importance of these
factors by demonstrating a good corre-
lation between the presence of blocking
factors of CMC in the sera of melanoma
patients and the clinical course of tumour
growth (Hellstrom and Hellstr6m, 1973;
Hellstrom et al., 1973).
During recent studies designed empiric-
ally to remove blocking factors of CMC
from the circulation of melanoma patients
by plasmapheresis, it was noted that
antibodies which could induce leucocyte-
dependent killing ofmelanoma cells (leuco-
cyte-dependent antibody, LDA) appeared
in their sera after the plasmapheresis
procedure (Hersey et al., 1976a). This
suggested that LDA activity was blocked
by factors in the sera of melanoma
patients similar to that proposed for
direct CMC, and that these phenomena
may be of equal importance in all-
owing escape of the tumour cells from the
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immune cytotoxic response of the host.
In this report we present evidence, from
in vitro studies, for the presence of serum
blocking factors against melanoma LDA,
based on LDA assays of fractions of sera
obtained by column chromatography and
by dissociation and ultrafiltration of
melanoma sera. Our results suggest that
"masking" of LDA activity may be the
usual finding in patients with disseminated
melanoma.
MATERIALS AND METHODS
Patients.-Sera were taken from patients
with melanoma attending the Melanoma
Unit, Sydney Hospital. H.I. and C.H. were
patients with disseminated melanoma who
had shown clinical improvement after sur-
gery and chemo-immunotherapy and had no
clinically detectable tumour. Patients J.S.,
C.Q., M.T., D.R., H.F. and B.N. had clinic
ally evident disseminated melanoma. Patients
B., R.G., N.D., R.L., D.T., M.C., A. and M.
had primary melanoma which was subse-
quently removed surgically. Sera were from
defibrinated blood samples and were stored
at -20°C in 2-3-ml-aliquots until use.
Gel exclusion chromatography.-Whole sera
were separated into several fractions on the
basis ofmolecular size using Sepharose CL-6B
(Pharmacia) in a column 2-6 x 70 cm (Type
K26/70, Pharmacia). Two ml of whole serum
was applied to the column and eluted with
0.9% saline containing 0.02% sodium azide
by upward flow at a rate of 0 5 ml/min at
4C. Fifty fractions of 6 ml each were
collected.
U.v. absorbance of the fractions was
measured at 280 nm on a Unicam SP1800 u.v.
spectrophotometer, and the fractions were
pooled into 4 groups according to molecular
size, on the basis of chromatogram results.
The large mol. wt fractions were concen-
trated back to 2 ml in an Amicon Diaflo cell,
using an XM100-A membrane, and the small
mol. wt fraction using a UM-2 membrane.
They were then dialysed twice against 500 ml
0-9% NaCl. Immunoglobulins in each were
identified byimmunodiffusion onTri-Partigen
plates (Hoechst).
Low-pH dissociation and ultrafiltration of
whole sera.-A modification of the method
described by Sjogren et al. (1971) and de
Schryver et al. (1976) was used in these
studies. Serum (0 5 ml) was diluted 1:10
with Sorensen's glycine buffer, pH 2-8, and
introduced into an Amicon Diaflo cell with
an XM100-A membrane (retaining molecules
>100,000 d). 45 ml buffer was added, drop-
wise, and allowed to stand at room tempera-
ture for 60 min. Filtration at 30 lb/in2 was
carried out to a volume of 1 ml and the pH
of both solutions was adjusted to pH 7-2
with 0-9M NaHCO3. The filtrate was then
concentrated in a Diaflo cell on a UM-2
membrane (retaining molecules >1000 d)
to 1-2 ml. Each fraction was then dialysed
twice against 500 ml of 0.9% saline for
16-18 h, and the components identified by
immunodiffusion on Tri-Partigen plates.
51Cr release assays.-The assay procedures
used have been described in detail in previous
reports (Hersey et al., 1976b).
Target cells (TCs).-Melanoma cells from
the continuous human line MM 200 were used
for most of the studies. These, as well as the
MM 127 and 170 lines used in the specificity
studies, were kindly supplied by Dr J. Pope
of the Queensland Institute of Medical
Research. The antigens expressed on the
surface of these cells have been described
previously (Hersey et al., 1976b). Chang cells
were from the continuous human liver cell
line (CSL, Melbourne). The ovarian carci-
noma cells were established from ascitic fluid
from metastatic ovarian carcinoma, and were
kindly supplied by the Department of Sur-
gery, University of Sydney. All TCs were
grown in RPM1 1640 (Gibco) supplemented
with 20% foetal bovine serum (FBS-
Australian laboratory services, Batch 42) and
were harvested by incubation with 0.25%
trypsin for 15 min immediately before use.
Effector cells.-Mononuclear cells were
obtained from defibrinated blood samples by
centrifugation on Hypaque-Ficoll mixtures
of sp. gr. 1 078 after methods described by
Boyum (1968). Unless otherwise stated, they
were from healthy laboratory volunteers.
The cells were resuspended in RPM1 1640 +
10% FBS at a concentration of 106ml for
use in the assays.
51Cr labelling.-TCs were labelled with
51Cr by incubation with 100 ,uCi of Na2CrO4
(Amersham, Bucks, U.K.) for 2 h. The
cells were washed twice in 25 ml of Eagles
minimal essential medium (MEM) (CSL,
Melbourne) and resuspended in RPM1 +
10% FBS at a concentration of 104/ml for
use in the assays.
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LDA assays.-Fractions obtained by the
chromatography procedures described, or by
low-pH dissociation and ultrafiltration, were
assayed for LDA by addition of 100 dul of
the fraction at the dilutions indicated to
cultures containing 5 x 103 in 500 jul of
5'Cr-labelled TCs (usually MM 200). This was
followed by the addition of 5 x 105 effector
cells in 500 pI. The cultures were in duplicate
(12 x 75) mm round-bottomed plastic tubes
(Sterilin, Filtrona, Melbourne). The tubes
were capped and incubated overnight for
16 h at 37°C in 7% Co2 in air. Assays were
terminated by centrifugation for 7 min at
400 g, and 500 jA of the supernatant removed
for estimation of 5'Cr release. Samples were
counted in an automatic Wallac 1280 gamma
counter.
Percent 5'Cr release was estimated by the
formula
a x 2-2
X~ 1 I00
test blocking material. (Where the added
test fractions had LDA activity, the baseline
was taken as for A above).
In experiments to test for affinity of
blocking activity to target cells, or inhibitory
activity to effector cells, 100 jA of the test
material was added to either target cell or
effector cell for 1 h at room temperature, anld
the tubes were then washed twice in 5 ml of
MEM. The tubes were drained and 100 t,l
of sensitizing IgG melanoma antibody added,
together with the effector cells in 1 ml of
medium. In these experiments control cul-
tures not exposed to the test material were
subjected to a similar washing procedure in
parallel with the test cultures.
Statistical analysis-.Student's t test was
used to compare the percent 5'Cr release of
cultures with and without LDA activity, and
to compare LDA activity in the presence or
absence of added blocking factors. Findings
were considered significant when P < 0 05.
where a= 5'Cr counts in the supernatant-
background count, and b = counts in tube
with remaining supernatant and cells-back-
ground counts. The LDA titre of sera or
fractions ofsera was taken as the last dilution
giving 5% 5'Cr release above the baseline
release of target cells and effector cells in the
absence of added sera or sera fractions. This
level of 5'Cr release was about 2 standard
errors from the points concerned, and was
taken as the minimum definite evidence of
LDA activity in the test.
Blocking of LDA assays.-Sera were tested
for blocking of LDA activity by addition to
cultures containing IgG known to induce
LDA reactivity against melanoma cells.
100 ,ul of the serum to be tested for blocking
activity was added to the TCs, followed by
100 dul of the sensitizing IgG antibody and
5 x 105 effector cells in 500 y1. Incubation
was carried out overnight and percent 5'Cr
release estimated as above, except that the
multiplication factor for "a" was 2-4. The
percentage inhibition or blocking of the anti-
body-dependent killing was estimated by the
formula
A-B
where A 00 5'Cr release induced by IgG
LDA above baseline of TC + effectors alone,
B 00% 5'Cr release induced by IgG LDA
above baseline of TC + effectors with added
RESULTS
LDA activity against melanoma cells of
whole sera and IgGfractions
Fig. 1 illustrates a representative assay
of LDA activity of whole serum and the
IgG fraction of serum from patient G.Q.
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FIG. 1. LDA activity of unfractionated
serum and the 7s fraction of serum from
a melanoma patient against MM 200 mela-
noma target cells and control non-mela-
noma "Chang" cells. LDA activity to mela-
noma cells is shown in the 7s fraction but
not the whole serum. TC = spontaneous
5'Cr release from target cell alone; TC +
Eff= 5'Cr release from target cell due to
natural cytotoxicity of the effector cells;
(s.e. mean < 2 %).
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with disseminated melanoma, against
melanoma cells from the MM 200 line and
the control Chang cell line. No LDA
activity was seen in the unfractionated
serum against the melanoma cell but the
IgG fraction had a titre of 1/102 to the
melanoma cells but not the control Chang
cells. In Table I similar studies are shown
in 8 patients with disseminated melanoma
and 8 with primary melanoma. Seven of
the 8 patients with disseminated mela-
noma had LDA activity in the IgG frac-
tion but not in their unfractionated sera.
Four patients with primary melanoma
had activity in the IgG fraction but not
in their unfractionated sera. The other 4
primary melanoma patients had no detect-
able LDA activity in either the IgG frac-
tion or the unfractionated sera. No sera
from 7 control normal subjects or 6 non-
melanoma subjects had LDA activity
in the IgG fraction against the MM 200
cell line. Negative data from sera of 2
patients with carcinoma of the breast
are not shown in the Table. (A.E. had
activity in both her whole serum and the
IgG fraction. Previous studies (Hersey
et al., 1976b) have suggested this activity
is against foetal antigens on the melanoma
cells. None of the sera or fractions of sera
from the melanoma patients tested had
detectable activity against the control
Chang cell. Serum A.E. reacted with
Chang cells to a titre of -%. Serum and
serum fractions from melanoma patients
H.I., G.Q. and M.C. did not have LDA
activity against the ovarian carcinoma
cells. None of the sera or serum fractions
in these studies had any effect on 51Cr
release when cultured alone with the
target cells in the absence of effector cells.
LDA reactivity of melanoma sera after
low-pH dissociation and ultrafiltration
Figure 2 illustrates the LDA activity of
serum from Melanoma Patient G.Q. and
serum fractions obtained from the whole
serum after lowering the pH to 2 8 and
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FIG. 2.-LDA activity of unfractionated
serumfrommelanomapatienttogetherwith
that of the retentate (A) and filtrate (B)
obtained after acidification to pH 2-8 and
ultrafiltration through membranes retain-
ing molecules greater than 100,000 d.
Activity is seen in retentate but not serum,
filtrate or combination offiltrate and reten-
tate. TC and TC + Eff are as described in
legend of Fig. 1. (s.e. mean < 2%).
TABLE I.-Comparison ofLDA Activity to Melanoma Cells of Unfractionated Sera
and the IgG-containing Fraction ofSera
Subjects with Subjects with
Non-melanoma Whole IgG disseminated Whole IgG primary Whole IgG
subjects serum fraction melanoma serum fraction melanoma serum fraction
E.S. 0 0 C.H. 0 102 B. 0 0
H.B. 0 0 H.I. 0 102 N.D. 0 10
B.M. 0 0 G.Q. 0 102 B.G. 0 0
J.Z. 0 0 H.F. 0 0 R.L. 0 10
A.E. 102 102 M.T. 0 10 D.T. 0 10
S.C. 0 0 J.S. 0 10 M.C. 0 102
P.M. 0 0 G.M. 0 10 A. 0 0
L.P.* 0 0 D.R. 0 10 M. 0 0
P.P.* 0 0
J.G.* 0 0
J.W.* 0 0
* Carcinoma other than melanoma (stomach, basal-cell carcinoma, lung and oesophagus, respectively).
Values indicated are reciprocal dilutions of sera or IgG fractions of sera, giving 51Cr release 5% above
baseline from target cell and effector cells alone.
Footnote: Spontaneous 5"Cr release from TCs ranged from 22 to 38%. 51Cr release due to cytotoxicity of
effector cells ranged from 5 to 15% above spontaneous release (see Fig. 1).
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ultrafiltration through an Amicon filter
retaining molecules greater than 100,000d.
Activity was seen in the retentate but not
in the whole serum or filtrate. Recom-
bination of filtrate and retentate resulted
in blocking ofthe activity ofthe retentate.
The retentate did not have LDA activity
against the control Chang cell.
The results in Table II indicate similar
studies on sera from 4 patients with
disseminated melanoma, 2 normal sub-
jects and 4 non-melanoma carcinoma
subjects. All of the melanoma sera had
LDA activity in the retained fraction
after dissociation and ultrafiltration, but
sera from the other subjects did not. Also
illustrated in the Table are control
studies showing that no LDA activity
was seen when the ultrafiltration was
carried out after restoration of the pH
to 7-4, or when saline instead of the
glycine buffer at pH 2-8 was added to the
serum. Only slight activity was seen when
ultrafiltration of the acidified serum was
carried out through membranes retaining
TABLE II. LDA Reactivity of Melanoma
kSera, Before and After Low-pH Dissocia-
tion and Ultrafiltration
Titre of LDA reactivity
Stubject
G.MA.
D.R.
H.T.
M.T.
m.T. (1)
M.T. (2)
M.T. (3)
E.A.*
P.M.*
(a) G.
(b) Pe
(c) W
((l) Pi
Whole
0
0
(0
0)
0
0
0
0)
0
0)
0)
Retainedl
fraction
102
10
102
1 0
0
0
0
0)
0)
0)
0)
0
0)
Filtrate
0
0
()
0 0 ()
()
()
()
0
Recombinedt
fractions
10(50)
10(50)
10(29)
0(75)
0
0
0)
0)
0)
0)
0)
Figtures in brackets represent °, inhibition of 51Cr
release above the baseline of TC and effector cells
alone, on recombination of the two fractions.
* Normal stubjects
(a) Carcin(oma of lutng, (b) stomach, (c) oesopha-
gtus, and (d) skin
(1) pH restor-ed to 7-4 before tultrafiltrationi, (2)
Ultrafiltration throuigh PM-10 instead of XM-100
membianes, (3) Ultrafiltration after ad(ition of
saline instea(d of glycine buffer at pH 2-8
See also footnote to Table 1.
molecules greater than I 0,000d, indicat-
ing that the blocking factors were between
10,000 and 100,OOOd.
Titration of blocking activity and affinity
of blocking activity for target cells or
effector cells
Experiments were conducted to deter-
mine the titre of blocking activity and
whether the blocking activity was directed
to the target cell or the effector cells. One
such experiment is illustrated in Fig. 3,
in which serum from Subject G.Q. was
added to MM 200 TCs sensitized with a
constant amount of the IgG fraction from
G.Q. Significant blocking activity was
still present at a titration of 1/104 of the
serum when present throughout the cul-
ture period. When the blocking serum was
added to the target cells and washed,
marked inhibition of the LDA activity
of added IgG was still shown. Blocking
was less marked however when the serum
was added to the effector cells and wash-
ing carried out.
Similar results to those illustrated in
Fig. 3 are shown in Table III. In all
experiments, the blocking activity of the
sera showed affinity for the target cell
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FIG. 3.-(A) Titration of blocking activity of
melanoma serum against melanoma IgG
LDA activity. (B, C) Blocking activity of
serum produced by preincubation with TC,
(B) effector cell (C) following by washing.
The sensitizing IgG LDA, and effector (B)
or target cells (C) were then a(lded. (Target
cells from MM 200 melanoma cell line.)
B.S. = blocking serum. TC and TC + Eff
are as described in legen(d to Fig. 1. IgG
refers to LDA activity of IgG fraction from
melanoma subject G.Q. In (B) and (C)
blocking serum was a(dle(l at a dilution of
s (s.e. mean < 2%)
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and little or no blocking was seen when
preincubated with the effector cells.
Specificity of the blocking activity of
melanoma
To determine the broad specificity of
the blocking activity to melanoma, sera
from patients with disseminated mela-
noma were added to cultures of Chang
cells sensitized with rabbit anti-Chang
serum (Hersey, Edwards and Edwards,
1976). As shown in Table IV, no blocking
of the killing of sensitized Chang cells by
leucocytes was seen. This applied even
when the IgG fraction from the melanoma
patient was present as well.
Initial studies to determine the specifi-
city of the blocking activity between
different melanoma patients are also
shown in Table IV. Blocking serum from
B.N. did not block the IgG LDA from
J.S. when the TC was MM 170, but did
when the TC was MM 127. M.T. serum
showed partial blocking of B.N. IgG
LDA.
DISCUSSION
From these initial studies it appears
that masking of LDA activity is a com-
mon finding in the sera of patients with
advanced melanoma, and to a lesser
extent inpatients with primary melanoma.
This has been demonstrated by several
methods, including separation of the IgG
fraction from sera by gel chromatography,
and acidification and ultrafiltration of
melanoma sera to dissociate and separate
immune complexes, similar studies to
those previously described by Sjogren et
al. (1971, 1972). In view of the suggested
biological importance of LDA in tumour
rejection (Lamon et al., 1973; Hersey,
1973; O'Toole et al., 1974) the presence
of these blocking factors against LDA
may be an important factor in allowing
escape of the tumour cells from this
immune cytotoxic mechanism.
The specificity of the LDA activity
detected in these sera has not yet been
extensively studied. However, none of
the melanoma sera or sera fractions
reacted with the control Chang liver cell,
and 3 of the strongly positive 7s fractions
from melanoma sera did not react with
ovarian carcinoma cells in culture. Per-
haps more importantly, we have not
shown LDA activity in the IgG-contain-
ing fractions of sera from 7 normal
subjects and 6 patients with various
malignancies other than melanoma. This
suggests that the LDA activity revealed
in the 7s fractions of melanoma sera is
related to melanoma. From our previous
studies on the specificity of LDA found in
melanoma sera, some reactivity against
non-melanoma cells may be expected
on the basis of cross-reacting foetal
antigens (Hersey et al., 1976b).
Several other questions arise from these
studies. One concerns the nature of the
blocking activity detected in these assays.
TABLE III.-Affinity ofBlocking Activityfor Target or Effector Cell8
Effect on IgG LDA Effect on IgG LDA
IgG LDA in activity of activity of
IgG presence of pre-incubation of pre-incubation of
Subject LDA whole serum TC effector cells
G.Q. 13 1* (92) 2* (83) 8 (38)
C.H. 10 0* (100) 5* (50) 10 (-)
M.T. 18 4* (78) 3* (83) 16 (11)
Values indicated are % '1Cr release induced by IgG LDA above baseline due to
cytotoxicity of AD effector cells in absence or presence of serum blocking factors.
(Maximum s.e. mean of the points was 2%.)
* P < 0* 05 for difference between IgG LDA activity in absence and presence of
blocking serum.
Figures in brackets are the percentage blocking activity of the IgG LDA pro-
duced by the whole serum in terms of inhibition of percent 5"Cr release above the
baseline.
See also footnote to Table I.
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TABLE IV.-Specificity ofSerum Blocking Activity against Melanoma LDA
Blocking
serum
M.T.
C.H.
J.S.
H.I.
P.M.**
L.S.**
M.T.
C.H.
C.H.
J.S.
J.S.
TC
MM 200
MM 200
MM 200
MM 200
MM 200
MM 200
Chang
Chang
Chang
Chang
Chang
Sensitizing
IgG LDA
M.T.
C.H.
J.S.
H.I.
E.H.
E.H.
Rabbit
anti-Chang
Rabbit
anti-Chang
Rabbit
anti-Chang + C.H.
Rabbit
anti-Chang
Rabbit
anti-Chang + J.S.
% 51Cr release above baseline
induced by LDA
No blocking serum Blocking serumt
12 5*
12 4*
6 1*
25 1*
15 14
15 14
11
8
11
10
8
8
8
8
10
9
J.S. MM 170 J.S. 13 5*
B.N. MM 170 J.S. 13 13
M.T. MM 127 B.N. 8 4
B.N. MM 127 J.S. 10 4*
*p < 0-05.
** Normal subjects.
t 1/10 final dilution.
(Maximum s.e. mean of the values was 2% 51Cr release.) See also footnote to Table I.
In common with the findings of Sjogren
et al. (1971, 1972) in studies on blocking
of direct CMC to tumour cells, we
have found that the blocking activity
against melanoma LDA can be dissociated
into large- and small-mol.-wt components
and that the small-mol.-wt component
was between 10,000 and 100,000 daltons.
This evidence suggested that immune
complexes were involved and that the
small-mol.-wt component may be tumour
antigen. The size of the antigen in these
studies would be consistent with that
described for melanoma antigens by
Currie (1973).
The second question relating to these
studies is the specificity of the blocking
activity. The results above indicate that
the blocking activity in the sera tested
was directed to the target cell and not the
effector cells. This was further shown by
the studies in which no blocking was seen
when the sera were added to LDA assays
of Chang cells sensitized with rabbit anti-
Chang serum. This latter test system was
shown previously to be inhibited non-
specifically by immune complexes inter-
acting with the effector cells (MacLennan,
1972). it was found in these studies that
complexes in slight antigen excess showed
maximum inhibition, and that complexes
in antibody excess had little or no inhibi-
tory activity. Our results therefore sug-
gest that if immune complexes are
responsible for the blocking activity they
are probably in antibody excess. This
would explain the absence of non-specific
blocking of LDA activity and the specifi-
city of the blocking activity for the target
cells. If this is so, it can be expected that
the specificity of blocking will be similar
to that described in our previous studies
(Hersey et al., 1976b) in which limited
cross-reactivity of antisera between dif-
ferent individuals with melanoma was
found.
The findings above appear to provide
an analytical assay system which we
anticipate may be useful in further
characterizing blocking factors. Prelimi-
nary results of work in progress also
suggest that the measurement of blocking
I
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activity against melanoma LDA may be
of value in monitoring patients with
melanoma.
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